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A scalably manufacturable oral antibody technology that can interfere with 
gastrointestinal (GI) targets is needed. Contrary to the complex native secretory IgA, we achieve 
this using a single-gene encoded monomeric-IgA-like antibody, composed of camelid VHH fused 
to IgA Fc (mVHH-IgA). This can be produced in soybean seeds or secreted from Pichia pastoris 
yeast, freeze- or spray-dried, and when delivered in food prevents enterotoxigenic Escherichia 
coli (F4-ETEC) infection in piglets.  
With the rapidly increasing knowledge of the role of the gut microbiome in diverse 
aspects of human and veterinary health, antibody-type drug-mediated methodology to 
specifically interfere with the microbiome or host factors in the gut is needed1-4. The challenge 
is that, unlike the systemically deliverable IgG1 scaffold-based antibodies, neither a 
comparable scaffold nor an integrated technology for orally deliverable antibodies is available. 
 The predominant antibody isoform at the GI mucosal surfaces is the secretory IgA 
(SIgA). SIgAs are complex tetravalent, abundantly glycosylated, heterodecameric antibodies, 
composed of four heavy chains, four light chains, a joining chain (J-chain) and a secretory 
component (SC) (Fig. 1a). SIgA is suitable for passive mucosal protection5-8, but recombinant 
SIgA production is challenging, as it requires expression and precise assembly of the 10 protein 
chains coded by four different genes6. There is also no industrially scaled affinity resin for 
downstream purification of SIgA9. Alternatively, expression and administration of antibodies in 
a food-grade matrix is attractive for GI-tract delivery, as it circumvents challenging purification 
and would allow for cost-effective scalable manufacturing.  
We previously showed that replacing the Fab of IgA with a camelid VHH antibody 
fragment can reduce the number of required genes from four to three to produce a seed-
bioencapsulated SIgA-analog (sVHH-IgA) in model plant Arabidopsis10. Feed containing seeds 
producing VHH-IgA formats protected, while monomeric VHH-IgG failed to protect piglets from 
F4 fimbriae-bearing enterotoxigenic E. coli (F4-ETEC) infection10. F4-ETEC is an important 
disease in pig rearing, causing economic losses due to post-weaning diarrhea, and is currently 
managed using antibiotics11. Mechanistically this swine infection is akin to cholera and ETEC-
caused traveler’s diarrhea in humans12.  
Nonetheless, introducing three genes in homozygous condition still makes translation 
to a scalable seed crop species (such as soybean; Glycine max) tedious, especially with crop 
lifecycle of up to 6 months, successive crossing would require several years. Therefore, using 
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the F4-ETEC piglet model, we first investigated whether a drastically simplified single-gene 
encoded monomeric VHH-IgA (mVHH-IgA) format would be efficacious in the gut (Fig. 1a). 
Arabidopsis seed stocks 10 were upscaled, containing four different anti-F4-ETEC VHH-IgAs 
(V1A, V2A, V3A and V4A), in either the sVHH-IgA or mVHH-IgA formats, wherein the VHH-IgA 
was about 0.2% of seed weight10. F4-ETEC-susceptible piglets receiving mVHH-IgA, sVHH-IgA 
or no antibodies (control group) in their feed were challenged with F4-ETEC (Fig. 1b, 
Supplementary Table 1a). Both the sVHH-IgA (p = 0.003) and mVHH-IgA (p = <0.001) fed groups 
had significantly lower shedding of the challenged strain vs. the control group (Fig. 1c). 
Although the mean shedding was low in the sVHH-IgA pen, a single piglet showed excessive 
shedding (>7 log10 colony forming units (CFU)) (Supplementary Table 2), which may have 
boosted the average seroconversion of this group (Fig.1d,e). The low anti-F4-ETEC IgG and IgA 
levels in the blood serum of the mVHH-IgA group (Fig. 1d,e) corroborated the immediate 
clearance of F4-ETEC by mVHH-IgA administered in feed. Our previous in vitro analysis showed 
that these antibody formats agglutinated F4-ETEC and prevent attachment to villous 
enterocytes10. 
This finding is important for translation, as a single transgene-requiring mVHH-IgA 
(dimerization-free and SC-free) is much easier to express in diverse expression systems. We 
hence produced mVHH-IgA in soybean. Soybean seeds containing mVHH-IgA at about 0.2% of 
seed weight were generated in sufficient amounts for a piglet trial, in about 1.5 years 
(Supplementary Fig. 1a). However, seeking an alternative to the time (about 10 years) and 
capital-intensive (possibly beyond 100 million USD) GM-plant regulatory pathway13, we 
successfully secreted functional mVHH-IgA from the yeast Komagataella phaffii (i.e., Pichia 
pastoris) (Supplementary Fig. 1b). Yeast-based protein expression is scalable and utilized to 
cost-effectively express industrial and food-processing enzymes14,15. However, the mVHH-IgA 
produced through the yeast secretory pathway (required for proper protein folding), is 
secreted into the growth medium and is no longer bio-encapsulated, unlike when it is 
produced in the plant seed. To investigate whether such non-encapsulated Pichia mVHH-IgA 
would be efficacious in blocking F4-ETEC, we conducted another piglet challenge experiment 
(Fig. 2). 
For this experiment the antibody cocktail was simplified, using equal proportion of V2A 
and V3A, as VHHs V1 and V2 bind to the same epitope, whereas V3 binds to another 
conformational epitope16. The Pichia-secreted and soybean produced mVHH-IgAs differed in 
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molecular weight due to differences in N-glycosylation (Supplementary Fig. 1). Based on 
average mVHH-IgA ELISA end-point titers of Pichia clones and the seed stocks, we observed 
that 1 ml of Pichia shake flash culture supernatant contained equivalent mVHH-IgA quantities 
as 5 mg of soybean or Arabidopsis seeds. Based on this ratio, experimental feeds were 
formulated aiming for piglet daily dose of 5 mg mVHH-IgA (V2A+V3A) produced in each system 
(a four-fold reduction in dose vs. the experiment in Figure 1).  
A purification-devoid simple scalable manufacturing process was established for edible 
Pichia mVHH-IgA (Fig. 2a). The Pichia culture medium was clarified by centrifugation, 
concentrated and buffer exchanged via diafiltration and mixed with pig feed, generating a 
slurry, which was dried in a food-grade lyophilizer. The process yielded consistent mVHH-IgA 
levels in four production batches (Supplementary Fig. 2). The freeze-dried batches were mixed 
with pig feed to attain 18 kg of Pichia mVHH-IgA feed (Fig 2a, Supplementary Table 1B). We 
validated the antigen-binding efficacy of the mVHH-IgAs in this formulation stored at room 
temperature for 2 years (Supplementary Fig. 3). For soybean and Arabidopsis, we added milled 
V2A- and V3A-producing seeds to piglet feed (Supplementary Table 1B). The mVHH-IgA 
quantity and quality were assessed in each feed formulation via immunoblot densitometry 
analysis and antigen-binding ELISA (Supplementary Fig. 3). 
On challenging with F4-ETEC (Fig. 2b), piglets receiving feed devoid of antibody showed 
successful colonization of the small intestine (Fig. 2c) but feed containing mVHH-IgA produced 
in Arabidopsis, soybean or Pichia prevented the F4-ETEC infection (Fig. 2c, Supplementary Table 
3). In mVHH-IgA receiving groups, F4-ETEC appeared to be swiftly cleared from the GI tract, as 
the shedding declined from day 3 onwards and remained low, often below detectable levels 
(2 log10 CFU) thereafter (Fig. 2c, Supplementary Table 3). Rapid clearance and immune-
exclusion of F4-ETEC was further supported by low anti-F4-ETEC seroconversion (Fig. 2d-e).  
Given this success, we further explored whether Pichia-derived mVHH-IgA, which is 
quite heat-resistant (first melting transition at about 65°C, Supplementary Fig. 4a) could be 
spray-dried, a low-cost industrial alternative to freeze-drying, which requires mVHH-IgA to 
withstand short but intense heating (~170°C). After spray-drying, the mVHH-IgA remained 
intact and retaining its antigen binding capacity (Supplementary Fig. 4).  
It is likely that a combination of several features enables the non-encapsulated Pichia 
mVHH-IgAs to work so efficiently in the GI tract. First, the VHH domain is small and robust17, 
facilitating drying, formulating in feed and intact gastric passage. Second, when secreted from 
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yeast, the IgA Fc molecules get modified with very large N-glycans (Supplementary Fig. 1b), 
possibly enhancing stability of the entire molecule. Third, the mixing of the antibodies with the 
feed into a dry product may further provide stability. 
Our future work will be directed toward translating this application for farm use. 
Subsequent farm-trials will enable mVHH-IgA impact assessment on F4-ETEC caused diarrhea 
and weight loss. As the porcine monogastric GI tract model has similarity to the human GI tract, 
future application development for human medicine appears warranted. 
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Figures 
 
 
Figure 1 Monomeric IgA in a plant seed matrix prevents F4-ETEC infection in piglets. The 
conventional secretory IgA was deconstruction to VHH-IgA based secretory IgA (sVHH-IgA) and 
monomeric IgA (mVHH-IgA) (a), produced in Arabidopsis seeds and delivered feed-admixed to 
evaluate efficacy in F4-ETEC challenged piglets (b), which showed that the mVHH-IgA fed group 
rapidly cleared the bacteria (c), and had correspondingly low seroconversion of anti-F4-ETEC 
IgG (d) and IgA (e) serum titers. The line graphs depict group mean and error bars represent 
the standard error of the mean. Statistical significance (p values) of changes in feed effects 
over time compared with negative control were assessed by an approximate F-test following a 
repeated measurements analysis using the residual maximum likelihood. 
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Figure 2 Pichia-secreted mVHH-IgA prevents F4-ETEC infection in piglets. Pichia-secreted 
mVHH-IgAs were produced in a simple integrated fashion as food ingredient and formulated 
in feed (a) to evaluate efficacy alongside feed admixed milled soybean or Arabidopsis seeds 
producing mVHH-IgA in an F4-ETEC piglet challenge experiment (b). Swift clearance and low 
shedding of F4-ETEC in groups fed with Pichia, soybean- and Arabidopsis-produced mVHH-IgA 
demonstrated protection (c), corroborated with low anti-F4-ETEC titers of serum IgG (d) and 
IgA (e). The line graphs depict group mean and error bars represent standard error of the 
mean. Statistical significance (p values) of changes in feed effects over time compared with 
negative control were assessed by an approximate F-test following a repeated measurements 
analysis using the residual maximum likelihood.  
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Online Methods  
  
VHH-IgA-based antibody production in different systems. The anti-ETEC mVHH-IgA and sVHH-
IgA producing Arabidopsis seeds were generated as described10. Briefly, the VHHs V1, V2, V3 
and V4 were selected from a llama immune library, such that they recognized the three 
circulating serotypes of the F4 fimbrial tip adhesin FaeG. The sequences of the respective VHHs 
were fused to that of porcine IgAb Fc, and expressed in Arabidopsis seeds under the control of 
the -phaseolin promoter and 3’ arcelin terminator. Within a similar expression cassette in 
separate T-DNAs, the porcine SC and J-chain were cloned. Starting from triple co-
transformation of SC, J chain and one of the VHH-IgAs, homozygous seed stocks accumulating 
high amounts of each of the VHH-IgA-based bivalent monomeric IgA (mVHH-IgA) were 
identified and named mV1A, mV2A, mV3A and mV4A. Furthermore, plants co-expressing 
porcine J-chain and SC with one of the VHH-IgAs, enabled generation of homozygous lines 
accumulating VHH-IgA-based tetravalent secretory IgA (sVHH-IgA), named sV1A, sV2A, sV3A, 
sV4A10. The four mVHH-IgA and sVHH-IgA lines were upscaled in the greenhouse to raise 150 
g seeds of each line to formulate the mVHH-IgA and sVHH-IgA feeds (daily dose 20 mg/day/pig) 
(Fig. 1 and Supplementary Table 1A). An additional 75 g of seeds containing mV2A and mV3A 
were raised to formulate a 5 mg daily dose for the Arabidopsis mVHH-IgA group in the second 
challenge experiment (Fig. 2 and Supplementary Table 1B).  
For expression of V2A and V3A in soybean seeds, the genes V2A and V3A from entry 
plasmid pEV2A and pEV3A10, were recombined into the Gateway expression vector pGW4318 
(Invitrogen). The resulting expression vectors were named pMXV2A and pMXV3A, and 
introduced into Agrobacterium strain EHA101 for transformation of the soybean plants 
(Glycine max cv. Williams 82) at the Plant Transformation Facility of Iowa State University, as 
described19. The VHH-IgA antibody accumulation was evaluated in the T2 seeds (first 
segregating seed stock) from extracts made by dissolving the seed powder obtained by drilling 
into one of the cotyledons without damaging the embryo axis, in the extraction buffer (50 mM 
Tris-HCl, 200 mM NaCl, 5 mM EDTA and 0.1% Tween 20 v/v, together with one cOmpleteTM 
(Sigma) protease inhibitor cocktail tablet per 50 ml of buffer). Serial dilutions of seed extracts 
were evaluated in ELISA with FaeG (serotype ‘ac’) antigen-coated wells (concentration of 1 
µg/ml in 0.1 M NaHCO3 pH 8.2) and detected with goat anti-pig IgA conjugated to horse-radish 
peroxidase (HRP) (BioRad), as described10. The same ELISA set up was used for evaluating VHH-
IgA produced in Arabidopsis or Pichia, henceforth referred to as FaeG-ELISA. Ten to twenty 
seeds from transformants expressing high amounts of antibody were retained for growing T2 
plants. To formulate the soybean-produced mVHH-IgA-bearing diet for the second piglet feed-
challenge experiment, 75 g of each, V2A (T5 seeds) and V3A (T2 seeds) producing seeds were 
used (Supplementary Table 1B).  
For V2A and V3A expression in Pichia, the VHH-IgA fusion genes V2A and V3A were 
PCR-amplified from pEV2A and pEV3A10 using the primer set Alfa-V2 (FW: 5’-
CTCTCTCGAGAAGAGAGAGGCCGAAGCTCAGGTGCAGCTGC-3’)  
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and IgA-NotI (REV: 5’-CCTCTTGAGCGGCCGCCCTTTAGTAGCATATGCCTTCTG-3’), as described 
for VHH-IgG20, and cloned in frame with the Saccharomyces cerevisiae mating factor prepro 
sequence within the pPpT4_Alpha_S expression vector21, which was linearized using the 
enzyme PmeI (NEB) and introduced into Pichia pastoris strain NRRL Y-11430 via 
electroporation22. The positive Pichia colonies were selected on YPD agar plated with 100 
µg/mL of Zeocin®. The expression of 20 individual colonies was analyzed in a 24-well system as 
described previously20. The medium containing the secreted VHH-IgA antibodies was typically 
harvested after 48 h of methanol induction. The expression level was evaluated via 
immunoblots and functional FaeG-ELISA, with and without Endoglycosidase T (Endo T) or 
Endoglycosidase H (Endo H)23 treatment for removal of N-glycosylations. Clones with high 
expression were identified and stored as glycerol-stock. As analytical standard, a carboxy-
terminal histidine tag version of V2A was expressed in Pichia as described above, purified using 
IMAC column chromatography and quantified using spectrophotometry at 280 nm. 
 
Seed-based antibody feed formulation. The soybean or Arabidopsis antibody-containing seeds 
were weighed (Supplementary Table 1), crushed in a chilled knife-mill (Retsch Grindomix 
GM200) and then mixed with pig feed (Voeders Van Haecke) in two steps to ensure thorough 
homogeneity. First as a premix of crushed seeds and pig feed with a hand-held electric balloon 
whisk (Braun), followed by mixing the premix with the pig feed in a fork dough mixer (150 L 
bowl capacity) for 30 min, to attain the daily antibody dose (20 mg or 5 mg, first and second 
challenge experiment, respectively) per 300 g of feed, which was the daily ration of feed 
accounted per piglet. To maintain equal nutrition in all groups throughout each experiment, 
flax seeds were used to replace Arabidopsis seeds. Additionally, in the second challenge 
experiment with soybean-produced antibodies, to account for the additional soybean proteins, 
wild-type soybean seeds were added to the Pichia, Arabidopsis and negative control groups at 
equal proportions (Supplementary Table 1B). All formulated feeds were bagged and stored at 
dry ambient temperature. 
 
Pichia-based antibody feed formulation. Cultures for either mV2A or mV3A were grown in 2l 
baffled shake-flasks in two batches of 7.5 l (i.e. 30 flasks each with 250 ml culture, per batch) 
amounting to 15 l. Cultures were grown for 48 h in BMGY medium (1% yeast extract, 2% 
peptone, 100 mM potassium phosphate, 1.34% yeast nitrogen base, 1% glycerol) up to 
stationary phase. Cells were induced by replenishing the medium with BMMY medium (1% 
yeast extract, 2% peptone, 100 mM potassium phosphate 1.34% yeast nitrogen base, 1% 
methanol) for 48 h. Induction was maintained by spiking the cultures with 1% (v/v) of methanol 
every 12 h. After 48 h of induction, the culture medium was harvested by centrifugation. The 
cell-free supernatant was concentrated via diafiltration to ~1.5 - 2 l and buffer-exchanged with 
a sodium-phosphate buffer (20 mM Na2HPO4, 18.75 mM NaCl, pH 6), using the CentramateTM 
500 S tangential flow filtration system (Pall Life Science) fitted with a 5-kDa OmegaTM 
Centramate filter cassette. To the resultant ~1.5-2 l protein solution containing Pichia-
produced mVHH-IgA, an equal weight of commercial pig feed (Voeders Van Haecke) was added 
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and mixed with a handheld paddle to avoid any foaming, and the slurry was lyophilized using 
a pilot-scale freeze dryer (Epsilon 2-10 D LSC- Martin-Christ, Germany) for 47 h. The resulting 
dried powder was then used as premix, which was further mixed in a fork dough mixer for 30 
min together with the pig feed to result in 18 kg of final Pichia-produced VHH-IgA-bearing feed 
(Supplementary Table 1B). All the formulated feeds were bagged and stored at dry ambient 
temperature.  
 
Evaluation of the mVHH-IgA in the final feed formulation. A 10% (w/v) suspension of the four 
final feed formulations (Pichia mVHH-IgA, soybean mVHH-IgA, Arabidopsis mVHH-IgA or 
negative control feed) was made in phosphate buffer saline. On brief centrifugation, the 
clarified fraction containing soluble proteins was analyzed via immunoblotting and ELISA assay. 
For immunoblot based analysis the samples were first treated with Endo H to remove N-glycan 
heterogeneity, resolved with SDS-PAGE under reducing conditions and probed with goat anti-
pig IgA polyclonal antibodies conjugated to HRP. A volume extract corresponding to 1.2 mg of 
the original dry material was loaded per well. Purified poly-histidine tagged mVHH-IgA V2A 
secreted from Pichia, similarly treated with Endo H was used in a 2-fold dilution series on the 
same blot as reference standard. For ELISA based analysis the samples were 5-fold serially 
diluted and tested in the FaeG-ELISA as described above.  
 
Piglet feed-challenge experiment. The Animal Care and Ethics Committee, Faculty of 
Veterinary Medicine, Ghent University, Belgium approved both of the piglet challenge 
experiments (ethical dossier number EC2014/02 and EC2015/47). The first challenge 
experiment aimed at comparing the efficacy of administrating 20 mg daily dose of Arabidopsis 
seed-contained mVHH-IgA or sVHH-IgA compared with no antibody in feed (Fig. 1) and the 
second at evaluating a four-fold lower (5 mg) daily dose of mVHH-IgA secreted from  Pichia, or 
contained in transgenic soybean or Arabidopsis seeds, administered in feed (Fig. 2). Suckling 
piglets (breed: Belgian Landrace) were screened from local farms, and those meeting the 
inclusion criteria of being seronegative for F4-ETEC and positive for the MUC13-genetic test24, 
which correlates with the presence of F4-ETEC receptors, were selected for the experiment. 
Eighteen piglets were sourced from a commercial farm for the first experiment, and 24 piglets 
from the farms of the ILVO institute for the second experiment. To prevent the contingency of 
F4-ETEC infection prior to the experiment, piglets from the commercial farm received 150,000 
U/kg dose of colistin orally at weaning and feed mixed with colistin (2 g/kg feed) for a week 
after weaning, as in our previous experiment10. Similarly, based on an antibiogram analysis, the 
piglets from the ILVO farm were intramuscularly administered amoxicillin instead of oral 
colistin, in a regimen of 0.1-ml dose on the day of birth and every other day until 6 days after 
birth, which was increased to a 0.6-ml dose administered on the day before weaning and 
further on the 2nd and 4th day post-weaning. This protocol was approved by the ILVO 
institutional ethics board (dossier number- EC2016/267).  
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On weaning, the piglets were brought to the laboratory stables, given ear tags, and 
housed in groups of six piglets each. The challenge procedure was performed as described 
previously10. Briefly, the piglets were challenged on two consecutive days with 1010 F4-ETEC 
bacteria (strain- GIS26Rstrep)10, via intragastric intubation under sedation after neutralization of 
gastric pH with bicarbonate buffer for 30 min. The first day of challenge is considered as day 0 
in the timeline. Prior to the challenge on day -3 and day -2, piglets were orally administered 1 
ml of Nuflor (florfenicol) and 2.5 mg/kg body weight of Baytril (enrofloxacin), to increase F4-
ETEC susceptibility by disturbing the gut microflora (dysbiosis). The specific modification, 
sample collection and manipulations with the animals, the group-specific feed regimen and 
day of euthanasia are schematically depicted in Fig. 1b and 2b, for the first and second 
challenge experiment, respectively. The antibody-containing feed was administered for 10 
days, starting three (Fig. 1b) or two (Fig. 2b) days before the challenge. During these 10 days, 
the daily experimental feed diet of 300 g per piglet was provided in a common feeding vat per 
group. The negative control group always received feed without antibody-containing 
substrate. To monitor the shedding of the F4-ETEC challenge strain GIS26Rstrep, dilutions of 
daily fecal samples were immediately plated on blood agar plates with streptomycin (1 mg/mL) 
selection. Serum antibody against the F4-fimbriae were determined according to the ELISA 
setup as described previously10. The serum was 2-fold serially diluted and endpoint titers are 
denoted as the first serum dilution having an OD value below the cut off. The cut off was 
calculated equal to the OD of a negative reference serum plus two times the standard 
deviation.  
An autopsy was performed post euthanasia, and the phenotypic expression of F4-ETEC 
receptors was confirmed on excised villous enterocytes in all piglets, as previously described10 
and showed 41 to 85 bacteria bound per 250 µm of the cell surface. One piglet from the group 
receiving 5 mg of Arabidopsis seed produced mVHH-IgA (piglet 18) was excluded from the 
analysis and statistical calculations, due to umbilical hernia detected post-mortem leading to 
extreme strangulation of the small intestine, but the data for this piglet is reported in 
Supplementary Table 3. CFU counts and titers below the detection limit were imputed with 
values generated as a random sample from a skewed left tailed beta distribution Beta (5,1) for 
plotting the graphs and statistical calculations. 
 
Melting curve determination. The purified histidine tagged version of V2A as described above, 
was used for determination of melting curve via the thermal shift assay using Sypro Orange, as 
described25. Melting curves were obtained for purified V2A within phosphate buffer saline or 
spray-drying buffer (20 mM Na2HPO4, 18.75 mM NaCl, pH 6 with 10% (w/v) maltodextrin). 
 
Spray-dried Pichia produced VHH-IgA. Fifteen liters each of mVHH-IgA V2A and V3A containing 
Pichia medium were produced in shake flask, subsequently concentrated and buffer 
exchanged as described above to one liter of retentate. The retentate was transported on ice 
and diluted to 25 l of sodium- phosphate buffer (20 mM Na2HPO4, 18.75 mM NaCl, pH 6) with 
10% maltodextrin. The liquid was mixed thoroughly using an industrial blender for 5-7 minutes 
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and then fed into the spray-drier, with parameters set to 45°C preheating of the feeding liquid, 
and 170°C inlet air temperature. During the drying process, the average outlet air temperature 
was about 80°C, and a constant liquid pumping speed was maintained. Approximately 2.3 kg 
of dried V2A and V3A containing powder was recovered. A 10% (w/v) solution of the mVHH-
IgA containing powder and of a control sample of the excipient used for spray-drying were 
evaluated for their functional antibody content in the FaeG-ELISA (Supplementary Fig. 4).  
 
Statistical analysis. Log-transformed shedding and titer longitudinal data were analyzed 
(repeated measurements over time) using the residual maximum likelihood (REML) as 
implemented in Genstat v18 (VSN International). Briefly, a linear mixed model (random terms 
underlined) of the form log(y) =  + feed + time +feed.time +pig.time was fitted to the 
longitudinal data. The term pig.time represents the residual error term with dependent errors 
because the repeated measurements are taken in the same individual, causing correlations 
among observations. Times of measurement were set as equally spaced, and the best model 
for correlation on the longitudinal data (e.g. uniform, autoregressive, antedependence, 
unstructured) was selected based on the likelihood ratio test (LRT) statistic and the Aikake 
Information Coefficient (AIC). Significance of feed effects over time (i.e. feed.time) and changes 
in differences between feed effects over time were assessed by an approximate F-test, of 
which the denominator degrees of freedom were calculated using algebraic derivatives as 
implemented in Genstat v18. Additional information is included in the Life Sciences Reporting 
Summary. 
 
Reporting summary. Further details of the experimental design can be found in the Life 
Sciences Reporting Summary linked to this article  
 
Data availability. The data of each piglet from the two challenge experiments plotted in Fig 1 
and Fig 2 are reported herein; the shedding data in Supplementary Table 2 and Supplementary 
Table 3, and the  serum titers in Supplementary Table 4 and Supplementary Table 5. Additional 
data is available from the corresponding authors on request.  
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Supplementary Figure 1 
Production of mVHH-IgA in soybean seeds and Pichia fermentate.  
(a) Representative immunoblots of V2A produced in Arabidopsis (At-V2A) and soybean (Gm-V2A), in which endoglycosidase T (Endo T) treatment 
leads to a mobility shift. A proteolytic fragment of <30 kDa is prominent in both plant species. (b) Pichia-based expression of V2A (Pp-V2A) and V3A 
(Pp-V3A) depicted in representative immunoblots, in which Endo T treatment shows a marked mobility shift due to removal of glycans. The 
immunoblots were repeated at least thrice with similar results.  
 
 
. 
Supplementary Figure 2 
The four batches of  freeze-dried Pichia  secreted mVHH-IgA produced for formulating the Pichia  mVHH-IgA feed contained 
s imilar proportions of  V2A and V3A. 
(a) Immunoblot analysis of 10% w/v resuspended solutions from the four freeze-dried batches, pre-treated with Endo H, shows similar band 
intensity. The volume loaded in each well corresponds to 1.2 mg of freeze-dried material. (b) ELISA titration curve depicting identical endpoint titers 
for each of the four batches of Pichia produced mVHH-IgA in binding the immobilised antigen FaeGac. The slope of V2A and V3A curves are different 
as the KD of the VHH V2 and V3 is quiet different (0.1 µM and 7.7 µM). The analysis was repeated at least twice with similar results. 
 
 
. 
Supplementary Figure 3 
The proportion of mVHH-IgA in the different feed formulations fed to the piglets.  
Equal part mix of mVHH-IgA V2A and V3A in the final feed formulations either secreted from Pichia (Pichia mVHH-IgA feed), or produced in soybean 
(soybean mVHH-IgA feed) or Arabidopsis (Arabidopsis mVHH-IgA feed) were analyzed as compared to negative control feed without mVHH-IgA. (a) 
Immunoblot of 10% (w/v) feed suspension extracts which were pre-treated with Endo H. The volume of feed extract loaded corresponds to 1.2 mg of 
each feed formulation. The densitometric analysis on the ~37kDa band, using the purified Endo H treated Pichia-secreted V2A dilution series as 
reference standards, corresponded to be 0.0011% for Pichia feed (3.3 mg in 300 gram daily feed), 0.0025% for soybean feed (7.5 mg in 300 gram 
daily feed) and 0.0013% for Arabidopsis feed (3.9 mg in 300 gram daily feed). (b-c) ELISA titration curves of the 10% (w/v) suspensions of all the 
experimental feed formulations containing mVHH-IgA (b) without Endo H pre-treatment and (c) with Endo H pre-treatment. In the latter case, the 
yeast N-glycan mediated inhibition of mVHH-IgA detectability in ELISA is eliminated, resulting in the curves and the endpoint titers as very similar. 
These analysis were repeated at least twice with similar results. 
 
 
 
 
Supplementary Figure 4 
Drying of  the Pichia-secreted mVHH-IgAs can be scaled up with spray-drying technology.  
(a) Purified V2A in spray drying buffer or in PBS (phosphate buffer saline) shows identical melting curve (first of two melting transition > 65°C) in 
thermal shift assay (b) A pilot-scale spray-dried mixture of Pichia secreted V2A and V3A (equal proportion), showed identical binding activity, before 
and after drying, to the immobilized antigen in ELISA. Maltodextrin (10%) was used as carrier in the spray-drying run, and also incorporated as 
negative control in the ELISA. These analysis were repeated twice. (c) Picture of the pilot-scale spray drying installation used, showing bottom 2/3rd 
of drying chamber and the cyclone (upper right). (d) Sample of the dried powder containing Pichia-secreted mVHH-IgAs. 
 		
 
 
	
Supplementary Table 1. Feed formulation for piglet challenge experiments. (A) Experiment comparing monomeric and secretory IgA 
(Fig. 1) and (B) experiment  comparing the monomeric IgA produced in seeds (Arabidopsis and soybean) and secreted from Pichia (Fig. 
2).  	
A Mixing step I Mixing step II  
  
 
Premix composition Experimental feed 
  
 
Antibody-bearing 
seeds 
 (kg) 
Flax seeds  
(kg) 
Pig feed  
(kg) 
Total premix 
(kg)  
Pig feed  
(kg) 
Total feed  
(kg) 
 
Monomeric IgA 0.6 (3.3%) 0 1.2 1.8 16.2 18 
 
Secretory IgA 0.6 (3.3%) 0 1.2 1.8 16.2 18 
 
Flax feed  0 3.24 (3.3%) 6.56 9.8 88.2 98 
 
        
B Mixing step I Mixing step II  
 
 
Premix composition Experimental feed 
 
 
Antibody-bearing 
seeds or material 
(kg) 
Flax seeds  
(kg) 
Soybean wild-
type seeds  
(kg) 
Pig feed  
(kg) 
Total premix 
(kg) 
Pig feed 
(kg) 
Total feed  
(kg) 
Arabidopsis IgA 0.15 (0.83%) 0 0.15 (0.83%) 1.7 2 16 18 
Soybean IgA 0.15 (0.83%) 0.15 (0.83%) 0 1.7 2 16 18 
Pichia IgA  5.368a  
(of 30 l culture) 
0.15 (0.83%) 0.15 (0.83%) 0.337 6 12 18 
Flax-soy feed  0 2.49 (0.83%) 2.49 (0.83%) 1.02 6 294 300 
a Lyophilized slurry of feed and Pichia VHH-IgA-bearing retentate liquid from 30 l culture. 
The inclusion percentage within the total feed is indicated between parentheses.  
	 	
 
 
Supplementary Table 2. Shedding of the F4-ETEC (log10) per gram of feces post challenge, from the groups fed with mVHH-IgA or sVHH-
IgA compared with the control group which received feed without antibodies. Also the F4-ETEC detected within a gram of caecal, ileal 
and jejunal content post-mortem is presented. 
  
 
Day 
 0  
Day  
1 
Day 
 2 
Day  
3 
Day  
4 
Day 
 5 
Day  
6 
Day  
7 
Day 
 8 
Day 
 9 
Day 
10 
Day 
11 
Day 
13 
Day 
19   
Post-mortem  
Caecum Ileum  Jejunum 
   
   
Co
nt
ro
l g
ro
up
 
Pig 1 X 5.72 5.90 7.10 7.77 4.89 3.48 2.74 2.30 X X X N.A X   X X X 
Pig 2 X 3.48 5.31 5.75 6.17 4.76 3.93 X X X X X X X   X X X 
Pig 3 X 5.11 5.97 6.13 N.A 5.89 5.16 4.23 X 2.00 X X X X   X X X 
Pig 4 X 3.30 5.95 6.38 4.99 4.20 X 2.78 X X X X X X   X X X 
Pig 5 X 4.98 4.90 6.64 8.29 7.02 5.85 4.24 2.81 X X X X X   X X X 
Pig 6 X 4.81 5.55 6.41 6.73 10.08 8.54 7.12 4.70 2.00 X 2.00 X X   X X X 
sV
H
H
-Ig
A 
gr
ou
p 
Pig 7 X 5.76 5.53 5.00 X X X X 2.30 X X X X X   X X X 
Pig 8 X X 3.00 X X X 2.95 2.00 3.40 2.48 X X X X   X X X 
Pig 9 X 4.48 3.00 7.37 7.55 9.04 6.95 4.30 X X X X X X   X X X 
Pig 10 X 3.81 3.30 X X 3.30 3.00 X 2.00 2.00 X X X X   X X X 
Pig 11 X X 4.23 3.00 2.00 X 3.60 X X N.A X X X X   X X X 
Pig 12 X X 4.60 X 6.24 4.00 X 3.04 X X X X X X   X X X 
   
 m
VH
H
-Ig
A 
gr
ou
p 
Pig 13 X 4.71 7.13 6.15 X X X X X X X X X X   X X X 
Pig 14 X X 5.60 X X X X X X X X X X X   X X X 
Pig 15 X 6.32 6.71 X 2.74 2.78 2.00 X X X X X X X   X X X 
Pig 16 X X 3.85 4.19 X X X X X X X X X X   X X X 
Pig 17 X 4.81 6.33 4.70 3.78 2.60 X X X X X X X 3.72   4.08 X X 
Pig 18 X 4.92 X 3.48 X 3.72 X X X X X X X X   X X X 
N.A – no feces available; X – no F4-ETEC detected   (CFU (log10) detection limit per gram of feces = 2) 	 	
	 	
 
 
Supplementary Table 3. Shedding of the F4-ETEC (log10) per gram of feces post challenge, from the groups fed with mVHH-IgA 
antibodies secreted from Pichia or contained in soybean or Arabidopsis seeds compared with the control group which received feed 
without antibodies. Also the F4-ETEC detected within a gram of caecal, ileal and jejunal content post-mortem is presented. 
  
  Day 
0 
Day  
1 
Day 
2 
Day 
3 
Day 
4 
Day 
5 
Day 
6 
Day 
7 
Day 
8 
Day 
9 
Day 
10 
Day 
11 
Day 
12 
Day 
14 
  post-mortem 
Caecum Ileum Jejunum  
So
yb
ea
n 
Pig 1 X 2.00 3.24 X 3.60 X X X X X X X X X   X X X 
Pig 2 X X 2.00 X X X X X X X X X X X   X X X 
Pig 3 X 4.74 4.33 3.71 4.19 4.37 5.43 4.64 3.67 2.48 2.30 X X X   X X X 
Pig 4 X X 5.38 2.60 4.04 X 2.00 2.60 X X X X X X   X X X 
Pig 5 X 4.89 4.93 4.00 3.85 2.00 3.08 3.49 3.90 2.48 2.00 X X X   X X X 
Pig 6 X 4.72 7.43 4.00 3.00 3.52 3.00 X X X 2.00 X X X   X X X 
Pi
ch
ia
 
Pig 7 X 2.30 X X X X X X 2.00 X X X X X   X X X 
Pig 8 X 2.78 X X X X X X X X 3.61 4.37 3.24 2.78   2.78 X X 
Pig 9 X X 4.92 3.85 2.48 X X X X X X X X X   X X X 
Pig 10 X X 5.62 3.00 X X X X X X X X X X   X X X 
Pig 11 X 2.74 4.26 X X X X X X X X X X X   X X X 
Pig 12 X X 3.60 2.00 3.00 2.00 3.48 2.30 2.00 3.00 2.00 X X X   X X X 
Ar
ab
id
op
sis
 
Pig 13 X X X 3.34 X 3.18 3.51 6.00 5.69 6.38 5.65 4.15 2.48 X   X X X 
Pig 14 X X X 5.85 3.60 4.04 4.43 3.15 2.30 2.00 2.00 X X X   X X X 
Pig 15 X 3.58 4.73 2.00 X 3.70 X 2.48 X X 2.81 X 3.50 2.60   4.32 X X 
Pig 16 X 7.05 6.95 4.65 3.00 X X X X X X 2.00 2.00 X   X X X 
Pig 17 X X 6.90 3.54 4.06 X 2.88 2.00 X X 2.48 X 2.00 X   2.00 X X 
Pig 18 X X X X X X X X X X X 2.00 2.30 X   3.24 3.04 3.51 
Co
nt
ro
l 
Pig 19 X X 2.00 6.26 7.79 6.83 6.67 6.37 3.90 X X X X X   X X X 
Pig 20 X 3.98 4.62 6.20 7.52 6.91 7.08 5.92 3.30 X X X X X   X X X 
Pig 21 X 3.93 6.24 8.09 7.88 7.56 7.24 7.38 3.78 2.30 X 2.00 2.00 X   X X X 
Pig 22 X N.A 3.98 5.64 5.69 4.76 5.98 4.87 2.48 X X X X X   X X X 
Pig 23 X 5.09 6.99 5.84 5.34 5.64 5.38 5.35 4.63 X 3.02 X X X   X X X 
Pig 24 X 5.26 4.95 6.98 6.79 6.47 5.85 3.30 2.00 X X X X X   X X X N.A	–	no	feces	available;	X	–no	F4-ETEC	detected	(CFU	(log10)	detection	limit	per	gram	of	feces	=	2)	
 
 
		
Supplementary Table 4. Reciprocal anti-F4-ETEC serum IgA and IgG titers of piglets from the F4-ETEC challenge 
experiment fed with mVHH-IgA or sVHH-IgA containing feed compared with the control group which received 
feed without antibodies (experiment of Fig. 1).  	
 Pig no. IgA  IgG 
   Day -1 day 7 Day 13 Day 18 Day -1 day 7 Day 13 Day 18 
N
eg
at
iv
e 
co
nt
ro
l 
gr
ou
p 
Pig 1 60 1280 640 160 10 160 1280 640 
Pig 2 60 320 320 80 10 80 320 320 
Pig 3 60 160 320 80 10 40 160 160 
Pig 4 60 160 160 160 10 40 320 160 
Pig 5 60 320 640 320 10 80 320 160 
Pig 6 60 640 1280 320 10 40 160 160 
sV
H
H
-Ig
A 
gr
ou
p 
Pig 7 60 80 2560 160 10 20 640 320 
Pig 8 60 320 160 80 10 20 320 320 
Pig 9 60 320 640 320 10 160 640 640 
Pig 10 60 60 80 60 10 10 160 80 
Pig 11 60 60 80 160 10 10 80 160 
Pig 12 60 320 320 320 10 80 320 640 
m
VH
H
-Ig
A 
gr
ou
p Pig 13 60 80 160 80 10 40 160 160 
Pig 14 60 60 160 160 10 20 160 80 
Pig 15 60 60 160 160 10 10 20 40 
Pig 16 60 80 80 80 10 20 40 80 
Pig 17 60 60 60 60 10 10 10 80 
Pig 18 60 80 60 80 10 20 20 80 		 	
 
 
Supplementary Table 5. Reciprocal anti-F4-ETEC serum IgA and IgG titers of piglets from the F4-ETEC challenge 
experiment fed with mVHH-IgA antibodies secreted from Pichia or contained in soybean or Arabidopsis seeds 
compared with the control group which received feed without antibodies (experiment of Fig. 2). 
   IgA  IgG 
 Pig no.  Day 1 Day 7 Day 14 Day 1 Day 7 Day 14 
So
yb
ea
n 
 
Pig 1 10 20 10 10 20 20 
Pig 2 10 10 10 10 10 20 
Pig 3 10 10 160 20 20 80 
Pig 4 10 10 10 20 10 20 
Pig 5 10 10 20 20 40 40 
Pig 6 10 10 20 10 40 40 
Pi
ch
ia
  
Pig 7 10 10 80 20 20 80 
Pig 8 10 10 10 10 10 40 
Pig 9 10 10 10 20 10 20 
Pig 10 10 20 20 20 40 80 
Pig 11 10 10 10 40 20 20 
Pig 12 10 10 80 10 10 40 
Ar
ab
id
op
sis
  
Pig 13 10 10 320 20 40 1280 
Pig 14 10 20 160 20 20 2560 
Pig 15 10 10 10 20 10 320 
Pig 16 10 10 20 40 20 640 
Pig 17 10 10 20 20 10 40 
Pig 18 10 10 20 20 20 80 
Co
nt
ro
l  
Pig 19 10 40 320 20 40 320 
Pig 20 20 20 160 40 80 320 
Pig 21 10 160 640 20 320 640 
Pig 22 10 40 320 20 40 160 
Pig 23 10 80 640 10 40 320 
Pig 24 10 80 320 10 20 160 		
